12月18日，兴齐眼药跌0.69%，成交额2.31亿元。两融数据显示，当日兴齐眼药获融资买入额2699.12万 元，融资偿还2830.95万元，融资净买入-131.84万元。截至12月18日，兴齐眼药融资融券余额合计11.87 亿元。 责任编辑：小浪快报 融券方面，兴齐眼药12月18日融券偿还1.73万股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量7.78万股，融券余额526.47万元，低于近一年40%分位水平，处于较低位。 资料显示，沈阳兴齐眼药股份有限公司位于辽宁省沈阳市沈河区青年大街125号企业广场B座30层，成 立日期1977年3月24日，上市日期2016年12月8日，公司主营业务涉及眼科药物研发、生产、销售。主营 业务收入构成为：滴眼剂82.15%，凝胶剂/眼膏剂16.70%，其他(补充)1.15%。 截至9月30日，兴齐眼药股东户数5.41万，较上期增加16.85%；人均流通股3480股，较上期减少 14.42%。2025年1月-9月，兴齐眼药实现营业收入19.04亿元，同比增长32.27%；归母净利润5.99亿元， 同比增长105.98%。 分红方面，兴齐眼药A股上市后 ...

Group 1 - The core viewpoint of the news is the performance and market position of Xingqi Eye Pharmaceutical, which saw a stock price increase of 5.01% to 78.00 CNY per share, with a trading volume of 1.249 billion CNY and a turnover rate of 8.64%, resulting in a total market capitalization of 19.137 billion CNY [1] - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, specializes in the research, production, and sales of ophthalmic drugs, with its main revenue sources being eye drops (82.15%), gel/ointment (16.70%), and other supplementary products (1.15%) [1] Group 2 - From the perspective of major fund holdings, Nord Fund has a significant position in Xingqi Eye Pharmaceutical, with its Nord Quality Consumption Fund (011078) increasing its holdings by 31,400 shares in the second quarter, totaling 133,600 shares, which represents 2.75% of the fund's net value, ranking as the seventh largest holding [2] - The Nord Quality Consumption Fund, established on February 10, 2021, has a current size of 251 million CNY and has achieved a year-to-date return of 19.76%, ranking 4494 out of 8226 in its category, with a one-year return of 17.79%, ranking 4502 out of 8099 [2] - The fund manager, Xie Yi, has been in the position for 10 years and 114 days, overseeing a total fund size of 272 million CNY, with the best return during his tenure being 125.72% and the worst being -24.32% [2]

Group 1 - The core point of the news is the performance of Xingqi Eye Pharmaceutical Co., Ltd., which saw a stock price increase of 5.01% to 78.00 CNY per share, with a trading volume of 1.249 billion CNY and a turnover rate of 8.64%, resulting in a total market capitalization of 19.137 billion CNY [1] - The company, established on March 24, 1977, and listed on December 8, 2016, specializes in the research, production, and sales of ophthalmic drugs, with its main revenue sources being eye drops (82.15%), gel/ointment (16.70%), and other products (1.15%) [1] Group 2 - From the perspective of fund holdings, a fund under Zheshang Securities Asset Management has a significant position in Xingqi Eye Pharmaceutical, with the Zheshang Huijin Transformation Driver fund (001540) holding 33,300 shares, accounting for 3.18% of the fund's net value, ranking as the ninth largest holding [2] - The Zheshang Huijin Transformation Driver fund was established on July 27, 2015, with a latest scale of 54.3128 million CNY, achieving a year-to-date return of 9.92% and a one-year return of 7.91% [2]

Core Points - The stock of Xingqi Eye Pharmaceutical increased by 5.05%, reaching a price of 74.95 CNY per share, with a trading volume of 9.83 billion CNY and a turnover rate of 7.23%, resulting in a total market capitalization of 183.89 billion CNY [1] Company Overview - Xingqi Eye Pharmaceutical Co., Ltd. is located in Shenyang, Liaoning Province, and was established on March 24, 1977. The company went public on December 8, 2016. Its main business involves the research, production, and sales of ophthalmic drugs [1] - The revenue composition of the company includes eye drops at 82.15%, gel/eye ointments at 16.70%, and other supplementary products at 1.15% [1] Shareholder Information - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2,516,300 shares, which represents 1.34% of the circulating shares. The estimated floating profit today is approximately 9.0588 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion CNY. Year-to-date returns are 24.28%, ranking 1813 out of 4219 in its category, while the one-year return is 31.22%, ranking 1616 out of 3866. Since inception, the return is 135.8% [2] Fund Manager Information - The fund manager of Southern CSI 500 ETF is Luo Wenjie, who has a cumulative tenure of 12 years and 185 days. The total asset scale of the fund is 138.999 billion CNY, with the best fund return during his tenure being 145.85% and the worst being -47.6% [3] Fund Holdings - Southern Fund's Southern Big Data 300 Index A (001420) also holds shares in Xingqi Eye Pharmaceutical, with 47,800 shares held in the second quarter, accounting for 0.93% of the fund's net value, ranking as the seventh largest holding. The estimated floating profit today is about 171,900 CNY [4] - The Southern Big Data 300 Index A was established on June 24, 2015, with a latest scale of 2.17 billion CNY. Year-to-date returns are 35.06%, ranking 1020 out of 4219, while the one-year return is 51.42%, ranking 611 out of 3866. Since inception, the return is 79.19% [4] Additional Fund Manager Information - The fund manager of Southern Big Data 300 Index A is Xie Rui, who has a cumulative tenure of 3 years and 246 days. The total asset scale of the fund is 2.012 billion CNY, with the best fund return during his tenure being 19.27% and the worst being -0.23% [5]

Group 1 - The core point of the news is the significant increase in the stock price of Xingqi Eye Pharmaceutical, which rose by 5.05% to 74.95 CNY per share, with a trading volume of 983 million CNY and a turnover rate of 7.24%, leading to a total market capitalization of 18.389 billion CNY [1] - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, specializes in the research, production, and sales of ophthalmic drugs, with its main business revenue composition being 82.15% from eye drops, 16.70% from gel/eye ointments, and 1.15% from other supplementary products [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Xingqi Eye Pharmaceutical, with its Guolian An New Selected Mixed A Fund (000417) increasing its holdings by 1,800 shares in the second quarter, totaling 16,800 shares, which represents 2.58% of the fund's net value, making it the sixth-largest holding [2] - The Guolian An New Selected Mixed A Fund, established on March 4, 2014, has a latest scale of 33.7121 million CNY, with a year-to-date return of 8.1% and a one-year return of 9.58%, ranking 5,947 out of 8,095 in its category [2] - The fund manager, Zhang Zhenyuan, has been in the position for 11 years and 323 days, managing total assets of 40.811 billion CNY, with the best fund return during his tenure being 387.76% and the worst being -35.8% [2]

Core Insights - On October 15, Xingqi Eye Pharmaceutical Co., Ltd. saw a stock price increase of 5.1%, reaching 69.02 CNY per share, with a trading volume of 390 million CNY and a turnover rate of 3.08%, resulting in a total market capitalization of 16.934 billion CNY [1] Company Overview - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, is located in Shenyang, Liaoning Province. The company specializes in the research, production, and sales of ophthalmic drugs [1] - The revenue composition of the company includes eye drops at 82.15%, gel/ointment at 16.70%, and other supplementary products at 1.15% [1] Shareholder Insights - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2.5163 million shares, which represents 1.34% of the circulating shares. The estimated floating profit today is approximately 8.4297 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a current scale of 113.438 billion CNY. Year-to-date returns stand at 27.41%, ranking 1733 out of 4220 in its category, while the one-year return is 30.04%, ranking 1557 out of 3857. Since inception, the fund has achieved a return of 141.75% [2] Fund Performance - The fund manager of Southern CSI 500 ETF is Luo Wenjie, who has a tenure of 12 years and 180 days. The total asset scale under his management is 138.999 billion CNY, with the best fund return during his tenure being 152.82% and the worst being -47.6% [3] - Another fund, Southern Big Data 300 Index A (001420), also holds a significant position in Xingqi Eye Pharmaceutical, with 47,800 shares, accounting for 0.93% of the fund's net value. The estimated floating profit today is around 160,000 CNY [4] - The Southern Big Data 300 Index A was established on June 24, 2015, with a current scale of 2.17 billion CNY. Year-to-date returns are 37.99%, ranking 973 out of 4220, while the one-year return is 51.94%, ranking 473 out of 3857. Since inception, the fund has achieved a return of 83.07% [4] Additional Fund Management Insights - The fund manager of Southern Big Data 300 Index A is Xie Rui, who has a tenure of 3 years and 241 days. The total asset scale under his management is 2.012 billion CNY, with the best fund return during his tenure being 24.17% and the worst being -0.02% [5]

Group 1 - The core point of the news is the significant increase in the stock price of Xingqi Eye Pharmaceutical, which rose by 5.1% to 69.02 CNY per share, with a trading volume of 399 million CNY and a turnover rate of 3.15%, leading to a total market capitalization of 16.934 billion CNY [1] Group 2 - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, is located in Shenyang, Liaoning Province. The company specializes in the research, production, and sales of ophthalmic drugs [1] - The main business revenue composition of Xingqi Eye Pharmaceutical includes eye drops at 82.15%, gel/eye ointments at 16.70%, and other supplementary products at 1.15% [1] Group 3 - From the perspective of fund holdings, one fund under Zheshang Securities Asset Management has a significant position in Xingqi Eye Pharmaceutical. The Zheshang Huijin Transformation Driver fund (001540) held 33,300 shares in the second quarter, accounting for 3.18% of the fund's net value, ranking as the ninth largest holding [2] - The Zheshang Huijin Transformation Driver fund, established on July 27, 2015, has a latest scale of 54.3128 million CNY and has achieved a year-to-date return of 11.05%, ranking 5540 out of 8161 in its category [2] - The fund manager, Chen Gujun, has been in position for 5 years and 270 days, with a total asset scale of 204 million CNY. The best fund return during his tenure is 39.87%, while the worst is -7.57% [2]

Core Viewpoint - The stock of Xingqi Eye Pharmaceutical has shown a significant increase in price and trading activity, reflecting positive market sentiment and strong financial performance in recent periods [1][2]. Financial Performance - For the first half of 2025, Xingqi Eye Pharmaceutical reported a revenue of 1.163 billion yuan, representing a year-on-year growth of 30.38% [2]. - The net profit attributable to shareholders for the same period was 335 million yuan, marking a substantial increase of 97.75% year-on-year [2]. Stock Performance - As of October 15, the stock price of Xingqi Eye Pharmaceutical was 67.00 yuan per share, with a year-to-date increase of 38.35% [1]. - Over the last five trading days, the stock has risen by 1.93%, while it has decreased by 5.71% over the past 20 days and increased by 25.61% over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders for Xingqi Eye Pharmaceutical reached 46,300, an increase of 8.71% from the previous period [2]. - The average number of tradable shares per shareholder increased by 28.79% to 4,066 shares [2]. Dividend Distribution - Since its A-share listing, Xingqi Eye Pharmaceutical has distributed a total of 1.166 billion yuan in dividends, with 985 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest shareholder, holding 3.498 million shares, an increase of 968,000 shares from the previous period [3]. - The Southern CSI 500 ETF ranked as the fourth-largest shareholder with 2.516 million shares, up by 764,100 shares [3].

Core Viewpoint - On September 19, Xingqi Eye Pharmaceutical experienced a decline of 5.1%, with a stock price of 67.96 yuan per share, a trading volume of 872 million yuan, a turnover rate of 6.64%, and a total market capitalization of 16.674 billion yuan [1] Company Overview - Xingqi Eye Pharmaceutical Co., Ltd. is located in Shenyang, Liaoning Province, and was established on March 24, 1977, with its listing date on December 8, 2016 [1] - The company's main business involves the research, production, and sales of ophthalmic drugs, with revenue composition as follows: eye drops 82.15%, gel/eye ointment 16.70%, and others 1.15% [1] Shareholder Information - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2.5163 million shares, which represents 1.34% of the circulating shares [2] - The estimated floating loss for the ETF today is approximately 9.1846 million yuan [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion yuan, and has achieved a year-to-date return of 27.4% [2] Fund Performance - The Southern Big Data 300 Index A (001420) holds 47,800 shares of Xingqi Eye Pharmaceutical, accounting for 0.93% of the fund's net value, ranking as the seventh largest holding [3] - The estimated floating loss for this fund today is about 174,300 yuan [3] - The Southern Big Data 300 Index A was established on June 24, 2015, with a latest scale of 2.17 billion yuan, and has achieved a year-to-date return of 37% [3]